Repligen에 대한 매도 수량은 투자자에게 Repligen의 주식 하락에 베팅하는 정도를 알려줍니다. 매도 수량 데이터는 2주마다 업데이트됩니다.

Repligen (NASDAQ:RGEN) 주식, 공매도 수량 보고

Repligen

Repligen, headquartered in Waltham, Massachusetts, is a global life sciences company that develops and sells bioprocessing equipment and supplies used in the manufacturing of biologic drugs, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Its customers include biopharmaceutical companies, contract development and manufacturing organizations, or CDMOs, and other life science companies. It sells four main product categories: filtration (including fluid management) is the largest category and was 54% of 2023 revenue, while chromatography, proteins, and process analytics were 20%, 16%, and 9%, respectively. Customers in North America, Europe, and Asia Pacific contributed 44%, 37%, and 19% of revenue, respectively.

News

Movers

ACHC

CVLT

CWAN

DRVN

FTDR

HWKN

IDCC

LUMN

RGEN

SHAK

ZETA

다음은 지난주 큰 폭의 상승세를 보인 7개의 중형주 주식이다. 이 주식들은 여러분의 포트폴리오에 있나요? 루멘 테크놀러지스(NYSE:LUMN)의 주가는 65.95% 상승했다. 이 회사는 데이터 센터의 AI 수요를 지원하기 위해 코닝과 차세대 광섬유 케이블 공급 계약을 체결했다.

쉐이크쉑와 루멘 테크는 지난주 최고 성과를 보여준 7개 중형주 중 일부 (7월 28일-8월 3일)

Repligen Corp

Canaccord Genuity analyst Kyle Mikson initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Hold rating and announces Price Target of $165.

Price Target

Initiation

Analyst Ratings

Canaccord Genuity Initiates Coverage On Repligen with Hold Rating, Announces Price Target of $165

Wolfe Research analyst Doug Schenkel initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Peer Perform rating.

Wolfe Research Initiates Coverage On Repligen with Peer Perform Rating

Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) released on Tuesday third-quarter adjusted EPS of 43 cents, up from 23 cents a year ago, beating the consensus of 33 cents.
The bioprocessing technology reported sales of $154.87 million, up 10% year-over-year, beating the <a href="https://www.benzinga.com/pressreleases/24/11/g41897469/repligen-reports-third-quarter-2024-financial-results" target="_blank" rel="noreferrer noopener">consensus of $153.23 million</a>.
Olivier Loeillot, president and CEO of Repligen, said, "I'm pleased to report strong third-quarter results, made possible by the excellent execution by our team and improving market conditions. We are encouraged to see strengthening CDMO and equipment sales in the quarter, each delivering year-over-year and sequential growth.&#8221;
The company reported record quarterly revenue for new modalities, a 20% increase year over year. CDMO and equipment revenues grew ~20% and 6% year-over-year, respectively, adding to confidence in a broader market recovery.
Guidance: Repligen raises 2024 EPS guidance from 17 cents-24 cents to 25 cents-32 cents compared to a consensus estimate of 54 cents.
Repligen expects 2024 adjusted EPS of $1.50-$1.58 compared to <a target="_blank" href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40044492/repligen-lowers-guidance-on-china-weakness-analyst-expects" rel="noreferrer noopener">prior guidance of $1.42-$1.49</a> and consensus of $1.43.
The company has narrowed sales guidance from $627 million-$642 million to $630 million-639 million versus the consensus of $628.98 million.
William Blair notes that after reaffirming expectations for low-double-digit organic growth in the second half of 2024 and receiving positive feedback from industry conferences, Repligen's third-quarter earnings show that the bioprocessing recovery is on track.
The company has narrowed its guidance, now expecting about 8% revenue growth in the fourth quarter compared to last year, aligning with William Blair's and market estimates and bioprocessing peers predicting mid- to high-single-digit growth for the year-end.
Additionally, Repligen highlighted strong sales in contract development and manufacturing (CDMO) and equipment, which is a positive sign.
The analyst believes Repligen is well-positioned for long-term growth thanks to its involvement in new modalities, strong R&amp;D capabilities, and clinical exposure.
William Blair maintained the <a href="https://www.benzinga.com/quote/RGEN/analyst-ratings" target="_blank" rel="noreferrer noopener">Outperform rating for Repligen</a>.
RGEN Price Action: Repligen stock is up 7.32% at $149.72 at publication Tuesday.
Read Next:
<ul>
<li><a href="https://www.benzinga.com/news/earnings/24/11/41906923/treehouse-foods-stumbles-as-sales-dip-and-griddle-recall-hits-q3-earnings-ceo-bets-on-future-margins" target="_blank" rel="noreferrer noopener">TreeHouse Foods Stumbles As Sales Dip And Griddle Recall Hits Q3 Earnings; CEO Bets on Future Margins</a></li>
</ul>
Photo: Courtesy Repligen

Analyst Color

Earnings

Guidance

Health Care

Tech

Trading Ideas

General

Repligen Q3 Earnings Beat Expectations, Highlights Improving Market Conditions, Analyst Says Well-Positioned For Long-Term Growth

This whale alert can help traders discover the next big trading opportunities.
Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity scanner.
Traders often look for circumstances when the market estimation of an option diverges away from its normal worth. Abnormal amounts of trading activity could push option prices to hyperbolic or underperforming levels. 
Here's the list of options activity happening in today's session: 
<table>
<thead>
<tr>
<th>Symbol</th>
<th>PUT/CALL</th>
<th>Trade Type</th>
<th>Sentiment</th>
<th>Exp. Date</th>
<th>Strike Price</th>
<th>Total Trade Price</th>
<th>Open Interest</th>
<th align="right">Volume</th>
</tr>
</thead>
<tbody>
<tr>
<td>HIMS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/16/26</td>
<td>$30.00</td>
<td>$42.6K</td>
<td>3.5K</td>
<td align="right">672</td>
</tr>
<tr>
<td>DOCS</td>
<td>PUT</td>
<td>TRADE</td>
<td>BEARISH</td>
<td>05/16/25</td>
<td>$62.50</td>
<td>$50.2K</td>
<td>2</td>
<td align="right">446</td>
</tr>
<tr>
<td>PFE</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>12/19/25</td>
<td>$30.00</td>
<td>$28.1K</td>
<td>7.0K</td>
<td align="right">252</td>
</tr>
<tr>
<td>AMGN</td>
<td>PUT</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/17/25</td>
<td>$315.00</td>
<td>$51.9K</td>
<td>1.1K</td>
<td align="right">72</td>
</tr>
<tr>
<td>TGTX</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>08/15/25</td>
<td>$35.00</td>
<td>$34.0K</td>
<td>38</td>
<td align="right">71</td>
</tr>
<tr>
<td>JANX</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BULLISH</td>
<td>12/20/24</td>
<td>$50.00</td>
<td>$36.6K</td>
<td>595</td>
<td align="right">61</td>
</tr>
<tr>
<td>CI</td>
<td>PUT</td>
<td>SWEEP</td>
<td>BEARISH</td>
<td>12/20/24</td>
<td>$340.00</td>
<td>$27.0K</td>
<td>49</td>
<td align="right">59</td>
</tr>
<tr>
<td>IONS</td>
<td>CALL</td>
<td>TRADE</td>
<td>BULLISH</td>
<td>01/15/27</td>
<td>$55.00</td>
<td>$25.0K</td>
<td>331</td>
<td align="right">50</td>
</tr>
<tr>
<td>NVO</td>
<td>CALL</td>
<td>SWEEP</td>
<td>NEUTRAL</td>
<td>01/17/25</td>
<td>$100.00</td>
<td>$41.7K</td>
<td>1.1K</td>
<td align="right">42</td>
</tr>
<tr>
<td>RGEN</td>
<td>CALL</td>
<td>TRADE</td>
<td>NEUTRAL</td>
<td>11/15/24</td>
<td>$130.00</td>
<td>$33.0K</td>
<td>21</td>
<td align="right">20</td>
</tr>
</tbody>
</table>

<h2>Explanation</h2>
These bullet-by-bullet explanations have been constructed using the accompanying table. 
• Regarding HIMS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HIMS#NYSE">HIMS</a>), we observe a call option trade with bullish sentiment. It expires in 430 day(s) on January 16, 2026. Parties traded 49 contract(s) at a $30.00 strike. The total cost received by the writing party (or parties) was $42.6K, with a price of $870.0 per contract. There were 3515 open contracts at this strike prior to today, and today 672 contract(s) were bought and sold. 
• Regarding DOCS (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DOCS#NYSE">DOCS</a>), we observe a put option trade with bearish sentiment. It expires in 185 day(s) on May 16, 2025. Parties traded 54 contract(s) at a $62.50 strike. The total cost received by the writing party (or parties) was $50.2K, with a price of $930.0 per contract. There were 2 open contracts at this strike prior to today, and today 446 contract(s) were bought and sold. 
• Regarding PFE (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/PFE#NYSE">PFE</a>), we observe a call option sweep with neutral sentiment. It expires in 402 day(s) on December 19, 2025. Parties traded 225 contract(s) at a $30.00 strike. This particular call needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $28.1K, with a price of $125.0 per contract. There were 7032 open contracts at this strike prior to today, and today 252 contract(s) were bought and sold. 
• Regarding AMGN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMGN#NASDAQ">AMGN</a>), we observe a put option trade with bullish sentiment. It expires in 66 day(s) on January 17, 2025. Parties traded 30 contract(s) at a $315.00 strike. The total cost received by the writing party (or parties) was $51.9K, with a price of $1730.0 per contract. There were 1132 open contracts at this strike prior to today, and today 72 contract(s) were bought and sold. 
• For TGTX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/TGTX#NASDAQ">TGTX</a>), we notice a call option trade that happens to be bullish, expiring in 276 day(s) on August 15, 2025. This event was a transfer of 50 contract(s) at a $35.00 strike. The total cost received by the writing party (or parties) was $34.0K, with a price of $680.0 per contract. There were 38 open contracts at this strike prior to today, and today 71 contract(s) were bought and sold. 
• For JANX (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/JANX#NASDAQ">JANX</a>), we notice a put option sweep that happens to be bullish, expiring in 38 day(s) on December 20, 2024. This event was a transfer of 61 contract(s) at a $50.00 strike. This particular put needed to be split into 3 different trades to become filled. The total cost received by the writing party (or parties) was $36.6K, with a price of $601.0 per contract. There were 595 open contracts at this strike prior to today, and today 61 contract(s) were bought and sold. 
• For CI (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CI#NYSE">CI</a>), we notice a put option sweep that happens to be bearish, expiring in 38 day(s) on December 20, 2024. This event was a transfer of 36 contract(s) at a $340.00 strike. This particular put needed to be split into 6 different trades to become filled. The total cost received by the writing party (or parties) was $27.0K, with a price of $750.0 per contract. There were 49 open contracts at this strike prior to today, and today 59 contract(s) were bought and sold. 
• For IONS (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/IONS#NASDAQ">IONS</a>), we notice a call option trade that happens to be bullish, expiring in 794 day(s) on January 15, 2027. This event was a transfer of 50 contract(s) at a $55.00 strike. The total cost received by the writing party (or parties) was $25.0K, with a price of $500.0 per contract. There were 331 open contracts at this strike prior to today, and today 50 contract(s) were bought and sold. 
• For NVO (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/NVO#NYSE">NVO</a>), we notice a call option sweep that happens to be neutral, expiring in 66 day(s) on January 17, 2025. This event was a transfer of 39 contract(s) at a $100.00 strike. This particular call needed to be split into 4 different trades to become filled. The total cost received by the writing party (or parties) was $41.7K, with a price of $1070.0 per contract. There were 1154 open contracts at this strike prior to today, and today 42 contract(s) were bought and sold. 
• Regarding RGEN (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>), we observe a call option trade with neutral sentiment. It expires in 3 day(s) on November 15, 2024. Parties traded 20 contract(s) at a $130.00 strike. The total cost received by the writing party (or parties) was $33.0K, with a price of $1650.0 per contract. There were 21 open contracts at this strike prior to today, and today 20 contract(s) were bought and sold. 
Options Alert Terminology 
 - Call Contracts: The right to buy shares as indicated in the contract. 
 - Put Contracts: The right to sell shares as indicated in the contract. 
 - Expiration Date: When the contract expires. One must act on the contract by this date if one wants to use it. 
 - Premium/Option Price: The price of the contract. 
For more information, visit our <a href="https://pro.benzinga.com/blog/how-to-understand-option-alerts/">Guide to Understanding Options Alerts</a> or read <a href="https://www.benzinga.com/markets/options">more about unusual options activity</a>. 
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Options

AMGN

DOCS

Hims & Hers Health, Inc. Class A Common Stock

HIMS

IONS

JANX

TGTX

10 Health Care Stocks Whale Activity In Today's Session

<figure class="table"> 
<table>
<tbody>
<tr>
<td colspan="3">CURRENT GUIDANCE (at November 12, 2024)</td>
<td>&nbsp;</td>
</tr>
<tr>
<td>FY 2024</td>
<td>GAAP</td>
<td colspan="2">Adjusted (non-GAAP)</td>
</tr>
<tr>
<td>Total Reported Revenue</td>
<td>$630M - $639M</td>
<td colspan="2">$630M - $639M</td>
</tr>
<tr>
<td>Year-over-Year Change</td>
<td>0% - 1%</td>
<td colspan="2">0% - 1%</td>
</tr>
<tr>
<td>Base Revenue Growth</td>
<td>-</td>
<td colspan="2">(1%) - 0%</td>
</tr>
<tr>
<td>Gross Margin</td>
<td>49.5% - 50.5%</td>
<td colspan="2">49.5% - 50.5%</td>
</tr>
<tr>
<td>Income from Operations</td>
<td>$12M - $17M</td>
<td colspan="2">$80M - $85M</td>
</tr>
<tr>
<td>Operating Margin</td>
<td>2% - 3%</td>
<td colspan="2">12.5% - 13.5%</td>
</tr>
<tr>
<td>Other Income (Expense)</td>
<td>$10M</td>
<td colspan="2">$27M</td>
</tr>
<tr>
<td>Adjusted EBITDA Margin</td>
<td>-</td>
<td colspan="2">17.5% - 18.5%</td>
</tr>
<tr>
<td>Tax Rate on Pre-Tax Income</td>
<td>33%</td>
<td colspan="2">20%</td>
</tr>
<tr>
<td>Net Income</td>
<td>$14M - $18M</td>
<td colspan="2">$85M - $89M</td>
</tr>
<tr>
<td>Earnings Per Share - Diluted</td>
<td>$0.25 - $0.32</td>
<td colspan="2">$1.50 - $1.58</td>
</tr>
</tbody>
</table>
</figure>

Repligen Raises FY24 Adj EPS Guidance from $1.42-$1.49 to $1.50-$1.58 vs $1.43 Est

Repligen Raises FY24 GAAP EPS Guidance from $0.17-$0.24 to $0.25-0.32 vs $0.54 Est; Narrows Sales Guidance from $627.00M-$642.00M to $630.00M-639.00M vs $628.98M Est

WIIM

Repligen shares are trading higher after the company reported better-than-expected Q3 EPS and sales.

Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) reported quarterly earnings of $0.43 per share which beat the analyst consensus estimate of $0.33 by 30.3 percent. This is a 86.96 percent increase over earnings of $0.23 per share from the same period last year. The company reported quarterly sales of $154.870 million which beat the analyst consensus estimate of $153.230 million by 1.07 percent. This is a 9.69 percent increase over sales of $141.192 million the same period last year.

Earnings Beats

Repligen Q3 2024 Adj. EPS $0.43 Beats $0.33 Estimate, Sales $154.870M Beat $153.230M Estimate

ABOS

ABSI

ACNT

ACTG

AENT

AGEN

AIOT

AIRG

ALIT

ALTG

AMBC

AMPS

AMTX

APEI

AREB

ARIS

ARMN

ATRA

AUTL

Avadel Pharmaceuticals plc - American Depositary Shares each representing one Ordinary Share

AVDL

AXSM

AZTA

BHIL

BLDE

BLFS

BLTE

The Beachbody Company, Inc. Class A Common Stock

BODI

BRTX

BTMD

BTTR

BWAY

BXSL

BZFD

CAMT

CART

CATX

CAVA

CBAT

CBLL

CCLD

CGEN

CHGG

CHMI

CLSD

CNNE

CRNX

CRON

CRVS

CRWS

CVAC

CXAI

DAVA

DAVE

DRCT

DYAI

EARN

EGAN

ELMD

ETON

EVCM

EVGO

EYEN

FENG

FGEN

FIHL

FLNG

FOUR

FTCI

GENI

GENK

GMGI

GOVX

GRAL

GRDN

GROV

GRPN

GRVY

Earnings Scheduled For November 12, 2024

Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) has been analyzed by 6 analysts in the last three months, revealing a diverse range of perspectives from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
<table>
<thead>
<tr>
<th></th>
<th style="text-align: right;">Bullish</th>
<th style="text-align: right;">Somewhat Bullish</th>
<th style="text-align: right;">Indifferent</th>
<th style="text-align: right;">Somewhat Bearish</th>
<th style="text-align: right;">Bearish</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Ratings</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">5</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>Last 30D</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>1M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>2M Ago</td>
<td style="text-align: right;">1</td>
<td style="text-align: right;">3</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
<tr>
<td>3M Ago</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
<td style="text-align: right;">0</td>
</tr>
</tbody>
</table>
The 12-month price targets, analyzed by analysts, offer insights with an average target of $188.33, a high estimate of $205.00, and a low estimate of $170.00. This current average represents a 1.91% decrease from the previous average price target of $192.00. 
<img src="https://www.benzinga.com/files/images/story/2024/1727362824_0.png" alt="price target chart" />
<h2>Interpreting Analyst Ratings: A Closer Look</h2>
An in-depth analysis of recent analyst actions unveils how financial experts perceive Repligen. The following summary outlines key analysts, their recent evaluations, and adjustments to ratings and price targets.
<table>
<thead>
<tr>
<th>Analyst</th>
<th>Analyst Firm</th>
<th>Action Taken</th>
<th>Rating</th>
<th>Current Price Target</th>
<th>Prior Price Target</th>
</tr>
</thead>
<tbody>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$205.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Brandon Couillard</td>
<td>Wells Fargo</td>
<td>Announces</td>
<td>Overweight</td>
<td>$180.00</td>
<td>-</td>
</tr>
<tr>
<td>Rachel Vatnsdal</td>
<td>JP Morgan</td>
<td>Raises</td>
<td>Overweight</td>
<td>$200.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Elizabeth Garcia</td>
<td>UBS</td>
<td>Lowers</td>
<td>Buy</td>
<td>$185.00</td>
<td>$205.00</td>
</tr>
<tr>
<td>Conor McNamara</td>
<td>RBC Capital</td>
<td>Maintains</td>
<td>Outperform</td>
<td>$190.00</td>
<td>$190.00</td>
</tr>
<tr>
<td>Jacob Johnson</td>
<td>Stephens &amp; Co.</td>
<td>Maintains</td>
<td>Overweight</td>
<td>$170.00</td>
<td>$170.00</td>
</tr>
</tbody>
</table>
<h3>Key Insights:</h3>
<ul>
<li>Action Taken: Analysts adapt their recommendations to changing market conditions and company performance. Whether they 'Maintain', 'Raise' or 'Lower' their stance, it reflects their response to recent developments related to Repligen. This information provides a snapshot of how analysts perceive the current state of the company.</li>
<li>Rating: Delving into assessments, analysts assign qualitative values, from 'Outperform' to 'Underperform'. These ratings communicate expectations for the relative performance of Repligen compared to the broader market.</li>
<li>Price Targets: Analysts explore the dynamics of price targets, providing estimates for the future value of Repligen's stock. This examination reveals shifts in analysts' expectations over time.</li>
</ul>
For valuable insights into Repligen's market performance, consider these analyst evaluations alongside crucial financial indicators. Stay well-informed and make prudent decisions using our Ratings Table.
<a href="https://www.benzinga.com/quote/RGEN/analyst-ratings?utm_source=Benzinga Insights">Stay up to date on Repligen analyst ratings.</a>
<h2>All You Need to Know About Repligen</h2>
Repligen Corp is a global life sciences company. It develops and commercializes innovative bioprocessing technologies and systems that increase efficiencies and flexibility in the process of manufacturing biological drugs. The company's customers include life science companies, global biopharmaceutical companies, and contract manufacturers worldwide. Repligen markets its products globally through a direct commercial organization in the U.S., Europe, and Asia, as well as through strategic partners in select markets. The majority of the company's revenue is generated in North America.
<h3>Repligen: Delving into Financials</h3>
Market Capitalization: With restricted market capitalization, the company is positioned below industry averages. This reflects a smaller scale relative to peers.
Revenue Growth: Repligen's revenue growth over a period of 3 months has faced challenges. As of 30 June, 2024, the company experienced a revenue decline of approximately -3.2%. This indicates a decrease in the company's top-line earnings. As compared to competitors, the company encountered difficulties, with a growth rate lower than the average among peers in the Health Care sector.
Net Margin: Repligen's net margin surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 2.16% net margin, the company effectively manages costs and achieves strong profitability.
Return on Equity (ROE): Repligen's ROE stands out, surpassing industry averages. With an impressive ROE of 0.17%, the company demonstrates effective use of equity capital and strong financial performance.
Return on Assets (ROA): Repligen's ROA surpasses industry standards, highlighting the company's exceptional financial performance. With an impressive 0.12% ROA, the company effectively utilizes its assets for optimal returns.
Debt Management: Repligen's debt-to-equity ratio is below the industry average at 0.37, reflecting a lower dependency on debt financing and a more conservative financial approach.
<h2>The Significance of Analyst Ratings Explained</h2>
Ratings come from analysts, or specialists within banking and financial systems that report for specific stocks or defined sectors (typically once per quarter for each stock). Analysts usually derive their information from company conference calls and meetings, financial statements, and conversations with important insiders to reach their decisions.
Analysts may enhance their evaluations by incorporating forecasts for metrics like growth estimates, earnings, and revenue, delivering additional guidance to investors. It is vital to acknowledge that, although experts in stocks and sectors, analysts are human and express their opinions when providing insights.
Which Stocks Are Analysts Recommending Now?
Benzinga Edge gives you instant access to all major analyst upgrades, downgrades, and price targets. Sort by accuracy, upside potential, and more. <a href="https://www.benzinga.com/premium/ideas/benzinga-edge-checkout/?t=be8be9arja3be22bz21&amp;utm_source=benzinga-insights">Click here to stay ahead of the market</a>.
This article was generated by Benzinga's automated content engine and reviewed by an editor.

Evaluating Repligen: Insights From 6 Financial Analysts

RBC Capital analyst Conor McNamara reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Outperform and maintains $205 price target.

Reiteration

RBC Capital Reiterates Outperform on Repligen, Maintains $205 Price Target

Repligen To Restate Financial Statements For 2023 And Early 2024, No Impact On Business Operations Or Strategic Outlook; Reaffirms 2024 Revenue Guidance, Adjusting FY Range To $627M-$642M After $6.6M Understatement

Wells Fargo analyst Brandon Couillard initiates coverage on Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Overweight rating and announces Price Target of $180.

Wells Fargo Initiates Coverage On Repligen with Overweight Rating, Announces Price Target of $180

Repligen shares are trading lower following a report suggesting the company has approached Maravai LifeSciences with a takeover offer.

Wall Street edged slightly higher on Friday, with major equity indices showing modest gains <a href="https://www.benzinga.com/markets">at midday in New York.</a>
Both the S&amp;P 500 and Nasdaq 100 are on track to record their best week since October 2023, driven by stronger-than-expected economic data that eased earlier concerns of a recession. If they close in the green, they will secure the seventh straight positive session. 
On Friday, the University of Michigan&#8217;s Consumer Sentiment Index for August exceeded expectations, adding to a series of positive data, including lower-than-anticipated jobless claims and strong retail sales growth reported the day before.
Gold was the standout performer, climbing 1.5% to reach a record high of $2,500 per ounce, as traders positioned themselves in anticipation of imminent Federal Reserve rate cuts.
This surge in gold prices boosted gold mining stocks, with the VanEck Gold Miners ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GDX#NYSE">GDX</a>) advancing over 2%.
Oil prices, however, dipped 1.6% amid reduced geopolitical tensions as Gaza ceasefire negotiations resumed in Doha, Qatar. In a joint statement, the United States, Qatar, and Egypt announced that Washington had presented a new proposal that has the potential to rapidly close gaps and lead to a swift agreement.
Meanwhile, Bitcoin (CRYPTO: <a class="ticker" href="https://www.benzinga.com/quote/btc/usd">BTC</a>) rose 1.6%, reaching $58,368.
<h3 class="wp-block-heading">Friday&#8217;s Performance In Major US Indices, ETFs</h3>
<figure class="wp-block-table is-style-stripes"> 
<table>
<tbody>
<tr>
<td>Major Indices </td>
<td>Price</td>
<td>1-day %chg</td>
</tr>
<tr>
<td>Russell 2000</td>
<td>2,142.44</td>
<td>0.2%</td>
</tr>
<tr>
<td>S&amp;P 500</td>
<td>5,552.80</td>
<td>0.1%</td>
</tr>
<tr>
<td>Dow Jones</td>
<td>40,619.51</td>
<td>0.1%</td>
</tr>
<tr>
<td>Nasdaq 100</td>
<td>19,507.26</td>
<td>0.1%</td>
</tr>
</tbody>
</table>
<figcaption class="wp-element-caption">Updated at 12:30 p.m. ET</figcaption></figure>
According to <a href="https://bzresearch.myclickfunnels.com/benzinga-pro-content-webinar-registration/?utm_source=BZprocontent081624&amp;t=be2bearmibe3na1">Benzinga Pro</a> data:
<ul>
<li>The&nbsp;SPDR S&amp;P 500 ETF Trust&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SPY#NYSE">SPY</a>)&nbsp;was 0.1% higher to $553.81.</li>
<li>The&nbsp;SPDR Dow Jones Industrial Average&nbsp;(NYSE:<a class="ticker" href="https://www.benzinga.com/stock/DIA#NYSE">DIA</a>)&nbsp;also rose 0.1% to $406.32.</li>
<li>The tech-heavy Invesco QQQ Trust Series (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/QQQ#NASDAQ">QQQ</a>) edged 0.2% up to $475.31.</li>
<li>The iShares Russell 2000 ETF (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/IWM#NYSE">IWM</a>) ticked 0.2% higher to $212.42.</li>
<li>The Communication Services Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLC#NYSE">XLC</a>), The Financials Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLF#NYSE">XLF</a>), and The Consumer Discretionary Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLY#NYSE">XLY</a>) outperformed, up by 0.5%. The Real Estate Select Sector SPDR Fund (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/XLRE#NYSE">XLRE</a>) lagged, down by 0.5%.</li>
</ul>
<h3 class="wp-block-heading">Friday&#8217;s Stock Movers</h3>
<ul>
<li>H&amp;R Block Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/HRB#NYSE">HRB</a>) rallied 15% following stronger-than-expected results last quarter.</li>
<li>Other stocks moving on earnings were Amcor plc (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/AMCR#NYSE">AMCR</a>), down 5%, Applied Materials Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/AMAT#NASDAQ">AMAT</a>), down 1.5%, Coherent Corp. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/COHR#NYSE">COHR</a>), up 8%, Flower Foods Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/FLO#NYSE">FLO</a>), down 0.3%, and Globant S.A. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/GLOB#NYSE">GLOB</a>), up 4.9%. </li>
<li>Repligen Corp. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) dropped 13% after making an acquisition offer to Maravai LifeSciences Holdings (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/MRVI#NASDAQ">MRVI</a>), a company specializing in vaccine capping reagents with a market value of $2.2 billion. Following the offer, Maravai&#8217;s shares surged by 23%.</li>
</ul>
Read Next:
<ul>
<li><a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/08/40420968/walmart-stock-one-of-the-most-compelling-retail-investments-7-analysts-highlight-ma">Walmart Stock &#8216;One Of The Most Compelling&#8217; Retail Investments: 7 Analysts Highlight Market Share Gains</a></li>
</ul>
Image created using artificial intelligence via Midjourney.

Equities

Large Cap

Macro Economic Events

Broad U.S. Equity ETFs

Commodities

Econ #s

Economics

ETFs

$BTC

AMAT

AMCR

COHR

SPDR Dow Jones Industrial Average ETF Trust

Market Vectors ETF Trust Market Vectors Gold Miners

GLOB

MRVI

XLRE

Select Sector SPDR-Consumer Discretionary

Wall Street Gains Ground As Consumer Sentiment Improves; Gold Hits Record Highs, Boosting Mining Stocks: What's Driving Markets Friday?

Repligen Corp Has Approached Maravai LifeSciences Holdings Inc With An Acquisition Offer; Maravai LifeSciences  Shares Halted To The Upside; Stock Up 11.17%

Benchmark analyst Robert Wasserman reiterates Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Hold.

Benchmark Reiterates Hold on Repligen

These seven mid-cap stocks were the best performers in the last week. Are they in your portfolio?
<ol>
<li>Lumen Technologies, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/LUMN#NYSE">LUMN</a>) shares jumped 65.95%. The company reached a supply agreement with Corning for next-generation fiber-optic cables to <a href="https://www.benzinga.com//node/40104952" target="_blank" rel="noreferrer noopener">support AI demands in data centers</a>.</li>
<li>Shake Shack, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/SHAK#NYSE">SHAK</a>) shares escalated 19.52% after the company reported <a href="https://www.benzinga.com//node/40104675" target="_blank" rel="noreferrer noopener">better-than-expected Q2 sales results</a>. Several analysts increased <a href="https://www.benzinga.com//node/40131307" target="_blank" rel="noreferrer noopener">their forecasts for the company</a>.</li>
<li>Parsons Corp NYSE: PSN) stock gained 15.42% after it reported better-than-expected Q2 results and raised its FY24 revenue outlook.</li>
<li>Clearwater Analytics Holdings, Inc. (NYSE:<a class="ticker" href="https://www.benzinga.com/stock/CWAN#NYSE">CWAN</a>) stock increased 15.23% after the company reported better-than-expected Q2 sales results and issued Q3 and FY24 <a href="https://www.benzinga.com//node/40081350" target="_blank" rel="noreferrer noopener">revenue guidance above estimates</a>.</li>
<li>Repligen Corp (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) stock upped 15.14%. The company reported <a href="https://www.benzinga.com/analyst-ratings/analyst-color/24/07/40044492/repligen-lowers-guidance-on-china-weakness-analyst-expects" target="_blank" rel="noreferrer noopener">Q2 earnings</a>, after which several analysts revised their price forecasts.</li>
<li>Frontdoor Inc (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/FTDR#NASDAQ">FTDR</a>) stock gained 15.09% following better-than-expected Q2 earnings.</li>
<li>NeoGenomics, Inc. (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/NEO#NASDAQ">NEO</a>) stock upped 14.47% after the company reported better-than-expected Q2 financial results and <a href="https://www.benzinga.com//node/40021917" target="_blank" rel="noreferrer noopener">raised its FY24 revenue guidance</a>.</li>
</ol>
Also Read:
<ul>
<li><a href="https://www.benzinga.com/news/24/08/40150484/microstrategy-intel-and-moderna-are-among-top-12-large-cap-losers-last-week-july-28-august-3-are-the" target="_blank" rel="noreferrer noopener">MicroStrategy, Intel And Moderna Are Among Top 12 Large Cap Losers Last Week (July 28-August 3): Are The Others In Your Portfolio?</a></li>
<li><a href="https://www.benzinga.com/news/24/08/40150236/doordash-and-exact-sciences-are-among-top-10-large-cap-gainers-last-week-july-28-aug-3-are-the-other" target="_blank" rel="noreferrer noopener">DoorDash And Exact Sciences Are Among Top 10 Large Cap Gainers Last Week (July 28-Aug 3): Are The Others In Your Portfolio?</a></li>
</ul>
Photo by YAO23 via Shutterstock

Shake Shack And Lumen Tech Are Among Top 7 Mid Cap Stocks With Max Gains Last Week (July 28-August 3): Are The Others In Your Portfolio?

Repligen Corporation (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) reported in-line earnings for its <a href="https://www.benzinga.com/quote/RGEN/earnings">second quarter on Tuesday</a>.
The company posted second-quarter sales of $154.1 million, almost in line with the consensus estimate of $154.12 million. The company reported an adjusted EPS of 33 cents, which is in line with the consensus but below $0.53 reported a year ago.
Tony J. Hunt, CEO of Repligen, said, "We delivered solid second-quarter revenue of $154 million and first-half revenue of $305 million, achieving our year-to-date sales target. We are very encouraged by orders in the quarter, with continued strength in Pharma demand and a pickup in CDMO activity. New modalities continued to show strong year-over-year momentum in both revenue and orders."
Repligen expects 2024 revenues of $620 million—$635 million, compared to prior guidance of $620 million—$650 million and the consensus of $636.6 million.
Repligen shares gained 5.3% to trade at $169.16 on Wednesday.
These analysts made changes to their price targets on Repligen following earnings announcement.
<ul>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62dfc8fc8032230001a272b4/rachel-vatnsdal">JP Morgan analyst Rachel Vatnsdal</a> maintained Repligen with an Overweight and raised the price target from $190 to $200.</li>
<li><a href="https://www.benzinga.com/analyst-stock-ratings/analyst/62d7f4a480322300019cafd5/elizabeth-garcia">UBS analyst Elizabeth Garcia</a> maintained Repligen with a Buy rating, while cutting the price target from $205 to $185.</li>
</ul>
Read More: 
<ul>
<li><a href="https://www.benzinga.com/trading-ideas/long-ideas/24/07/40068197/jim-cramer-says-this-home-improvement-chain-is-a-buy-ahead-of-fed-rate-cut-cycle-i-would">Jim Cramer Says This Home Improvement Chain Is A Buy Ahead Of Fed Rate Cut Cycle: &#8216;I Would Pick Some Up Tomorrow&#8217;</a></li>
</ul>

Markets

These Analysts Revise Their Forecasts On Repligen Following Q2 Results

JP Morgan analyst Rachel Vatnsdal maintains Repligen (NASDAQ:<a class="ticker" href="https://www.benzinga.com/stock/RGEN#NASDAQ">RGEN</a>) with a Overweight and raises the price target from $190 to $200.

JP Morgan Maintains Overweight on Repligen, Raises Price Target to $200

Harding Loevner Global Equity ADR Q3 2024 Report

TimesSquare U.S. Mid Cap Growth Q3 2024 Commentary

Harding Loevner Global Developed Markets Equity Q3 2024 Report

Polen U.S. Small Company Growth Q3 2024 Commentary

Repligen (RGEN) announced the launch of AVIPure dsRNA Clear OPUS columns, a solution designed to simplify and enhance the production of mRNA therap...

Repligen launches AVIPure dsRNA Clear OPUS columns

BNY Mellon Small/Mid Cap Growth Fund Q3 2024 Commentary

In a report released on December 8, Conor McNamara from RBC Capital maintained a Buy rating on Repligen (RGEN – Research Report), with a price targ...

RBC Capital Reaffirms Their Buy Rating on Repligen (RGEN)

Allspring Premier Large Company Growth Fund Q3 2024 Commentary

BioLife Solutions (BLFS) (BFLS) announces the appointment of Tony Hunt, Executive Chairman of Repligen Corporation (RGEN) and a recognized leader i...

BioLife Solutions appoints Hunt to board of directors

Canaccord initiated coverage of Repligen (RGEN) with a Hold rating and $165 price target The company delivers configurable bioprocessing products a...

Comments

Repligen

매도 수량

Repligen (NASDAQ:RGEN) 주식, 공매도 수량 보고

사람들이 또한 지켜본다

뉴스

파트너 / 기고자

벤징가 글로벌